ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance of commercially available, targeted anticancer drugs prescribed for the treatment of patients with advanced cancers that have a potentially actionable genomic variant.

TAPUR aims to:

  • Collect data on clinical outcomes to learn about new uses of these drugs outside of indications approved by the Food and Drug Administration
  • Learn from the real-world practice of prescribing targeted therapies to patients whose tumors harbor a genomic variant known to be a drug target
  • Educate oncologists about implementation of precision medicine in clinical practice
  • Catalogue the choice of genomic profiling test by clinical oncologists and learn about the utility of registry data to develop hypotheses for additional clinical trials

Visit the TAPUR Study website to:

  • Enquire about having your clinical site participate in the TAPUR Study
  • Learn more about serving on the study Molecular Tumor Board
  • Learn more about the latest TAPUR Study news and updates
  • Review the current list of participating centers enrolling participants (additional centers will be brought on throughout the study, so please check frequently for updates!)